Ngan Olivia Miu Yung, Yi Huso, Ahmed Shenaz
CUHK Centre for Bioethics, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR.
Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Tahir Foundation Building, 12 Science Drive 2, #09-01W, Singapore, 117549, Singapore.
BMC Health Serv Res. 2018 Sep 21;18(1):731. doi: 10.1186/s12913-018-3540-9.
Cell-free fetal DNA sequencing based non-invasive prenatal testing (NIPT) for Down syndrome (DS) has become widely available. In Hong Kong, obstetric providers in the public sector refer women identified at high risk of having a child with Down syndrome to obstetric providers in the private sector for NIPT. Little is known about how the NIPT has been adopted in the public sector where DS screening is provided for free of charge. The study aimed to identify the factors influencing providers' role enactment, such as consultation and referral, in the service provision of NIPT for DS in public and private healthcare sectors.
In-depth interviews were conducted with 20 obstetric providers offering NIPT in Hong Kong. Thematic narrative analysis was used to identify (i) the factors considered by participants when referring women for NIPT for Down syndrome in public and private healthcare sectors and (ii) their perceptions of the need to integrate NIPT into the current public antenatal service.
Participants raised concerns about the lack of transparent referral guideline between public and private sectors for NIPT. Public obstetric providers reported little obligation to provide women with much information about risks and benefits of NIPT as it was not provided by public sectors. Some private providers assumed that women referred from the public sector had already received sufficient information about NIPT. The providers were also concerned about potential application of NIPT for further detection without regulation.
Although the providers had good knowledge of clinical advantages of NIPT over conventional screening, they were uncertain about how to introduce NIPT to women. Guidelines are necessary to enable better coordination of public and private sectors services to enable women to make informed choices about the uptake of NIPT.
基于游离胎儿DNA测序的唐氏综合征(DS)无创产前检测(NIPT)已广泛应用。在香港,公共部门的产科医护人员会将被确定为生育唐氏综合征患儿高风险的女性转介至私营部门的产科医护人员处进行NIPT检测。对于在免费提供DS筛查的公共部门中NIPT是如何被采用的,人们知之甚少。该研究旨在确定影响医护人员在公共和私营医疗部门提供DS的NIPT服务时进行咨询和转诊等角色履行的因素。
对香港20名提供NIPT的产科医护人员进行了深入访谈。采用主题叙事分析来确定:(i)公共和私营医疗部门的参与者在将女性转介进行唐氏综合征NIPT检测时所考虑的因素;(ii)他们对将NIPT纳入当前公共产前服务必要性的看法。
参与者对公共和私营部门之间缺乏NIPT透明转诊指南表示担忧。公共部门的产科医护人员表示,由于公共部门未提供相关信息,他们几乎没有义务向女性提供关于NIPT风险和益处的大量信息。一些私营部门的医护人员认为,从公共部门转介来的女性已经获得了足够的NIPT信息。医护人员还担心NIPT在没有监管的情况下用于进一步检测的潜在应用。
尽管医护人员深知NIPT相对于传统筛查的临床优势,但他们不确定如何向女性介绍NIPT。需要指南来更好地协调公共和私营部门的服务,使女性能够就接受NIPT做出明智的选择。